Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune closed an oversubscribed public offering, raising approximately $225 million in gross proceeds to fund its Phase 3 pemvidutide trial in MASH. The offering consisted of 64.25 million shares of common stock and accompanying warrants, priced at a combined $3.00 per unit, with top-tier investors including Deep Track Capital and RA Capital Management participating.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.